

PPP

Clinical Hint: G6PD Deficiency

→ catalyzes 1st step of PPP.
G-6-P → 6-P6

القول

- A common disease
- characterized by hemolytic anemia
- 200 – 400 millions individuals worldwide ⇒ v. common
- Highest prevalence in Middle East, S.E. Asia, Mediterranean
- X-linked inheritance ⇒ males are ↑ susceptible.
- > 400 different mutations ⇒ until now, mutations were found to be point mutations. ⇒ expect to find various phenotypes + severities of the disease.
- Deficiency provides resistance to falciparum malaria ⇒ targets RBCs

Precipitating Factors in G6PD Deficiency

⇒ ↓NADPH = ↑ROS = cell death.

↳ anything that can increase ROS levels works as a (risk) factor
examples ↓ in these patients → crisis.

- Oxidant drugs

- Antibiotics e.g. Sulfomethazole
- Antimalaria Primaquine
- Antipyretics Acetanalid

- Favism due to vicine and convicine in fava beans in some G6PD deficient patients

- Infection

- Neonatal Jaundice ⇒ yellow skin in newborns

↳ has to with degradation process of heme groups ⇒ degradation produces bilirubin ⇒ v. destructive of CNS esp. in kids.
yellow


↳ not a disease, developmental process (waiting for enough enzyme formation to get rid of bilirubin)

↓
if newborn has jaundice & G-6-P DH deficiency ⇒ more susceptible to oxidative stress.

Role of G6PD in red blood cells




GSH helps maintain the SH groups in proteins in the reduced state
Oxidation → denaturation of proteins and rigidity of the cells



Classification of G6PD Deficiency Variants

Although the activity of the normal enzyme declines as red cells age, even the oldest cells have a sufficient level of activity to provide protection against oxidative damage and hemolysis.



By contrast, very few *G6PD Mediterranean* red cells have sufficient enzyme activity to prevent oxidative damage, whereas a substantial fraction of young *G6PD A⁻* red cells are able to provide protection.

Class	Clinical symptoms	Residual enzyme activity
I	almost absent Very severe	<2%
II	Severe	<10%
III	Moderate	10-50%
IV	None	> 60%


- Wild type B
- Mediterranean Variant B⁻ (Class II) : 563C → T
- African Variant A⁻ (Class III); two point mutation
- Majority missense mutation, point mutation
- Large deletions or frame shift; Not Observed

Lipid Digestion

Celiac disease (CD) symptoms similar to malnutrition.



autoimmune disease

- Fat malabsorption leading to steatorrhea (excess lipids in feces) significant sign of CD
Fat droplets in feces (beez hydrophobic)
- It is an autoimmune response to gliadin, a peptide found in gluten (wheat, rye, and barley). should not be found in AF contents
at gluten as a protein is composed of gliadin & glutenin
when H₂O is added to wheat, gliadin & glutenin will interact forming gluten.
- Gliadin contains many proline (14%) and glutamine (40%) residues, making it resistant to digestion. inter-feres with digestive enzymes
- Lab tests: the presence of anti-tissue transglutaminase (anti-tTG) antibodies. antibodies against the enzyme working on glutamine metabolism
- Tissue biopsy: absence of villous surface epithelial cells resulting in decreased nutrient absorption.



seen in diseases other than CD.
Principal causes of steatorrhea:

- Short bowel disease** → shorter small intestine than normal → less digestion & absorption
- Liver or biliary tract disease** is: gallbladder stone
- Pancreatic exocrine insufficiency** Cl⁻ ion channel
- Cystic fibrosis** CFTR protein → CFTR gene is mutated → problem in Cl⁻ movement
H₂O movement is affected
exocrine secretions become thick (↓ H₂O content)
blockage → infection → antibiotic usage
could affect respiratory tract / GI



FA Degradation

Application: Carnitine deficiencies

- Primary carnitine deficiency
 - Defects in a membrane transporter: ^(translocase) No uptake of carnitine by cardiac and skeletal muscles and the kidneys, causing carnitine to be excreted.
 - Treatment: carnitine supplementation.
- Secondary carnitine deficiency
 - Taking valproic acid (antiseizure) → decreased renal reabsorption ⇒ more excretion.
 - Defective fatty acid oxidation ^(enzymes) → acyl-carnitines accumulate → urine ^{activated FAs accumulation} ⇒ appears like carnitine deficiency.
 - Liver diseases → decreased carnitine synthesis ^{bcz it's synth. in liver.}
 - ① CPT-I deficiency: ^{transferrases:} affects liver; no use of LCFA, no energy for glucose synthesis during fasting → severe hypoglycemia, coma, and death
 - ② CPT-II deficiency: ^{f.a stays bound to carnitine} affects liver, cardiac muscle, and skeletal muscle
 - Treatment: avoidance of fasting and adopting a diet high in carbohydrates and low in fat but supplemented with medium-chain TAG. ^{+ ketogenic diet} ⇒ small + v. frequent meals.
 ⇒ not highly obtained from diet.




Application: MCAD deficiency

- There are 4 isozymes of fatty acyl CoA dehydrogenase for SCFA, MCFA, LCFA, and VLCFA.
- Medium-chain fatty acyl CoA dehydrogenase (MCAD) deficiency,

- An autosomal-recessive disorder
- Most common inborn error of β -oxidation (1:14,000 births worldwide)
- Higher incidence among Caucasians of Northern European descent
- Decreased ability to oxidize MCFAs (lack of energy)
- Severe hypoglycemia and hypoketonemia
- Treatment: avoidance of fasting

Regular and frequent meals and snacks
Diet high in carbohydrates and low in fat




Glycerophospholipids

Application: Surfactants

- Surfactants are a complex mixture of lipids (90%) and proteins (10%) that make the extracellular fluid layer lining the alveoli and are secreted by type II pneumocytes in the lungs.
- Dipalmitoylphosphatidylcholine (DPPC) is the major lipid in surfactants.
- Surfactants serve to decrease the surface tension of the fluid layer allowing reinflation of alveoli and preventing alveolar collapse (atelectasis).
- Respiratory distress syndrome (RDS) in preterm infants is associated with insufficient surfactant production and/or secretion.
- Prenatal administration of glucocorticoids shortly before delivery to induce expression of specific genes.

in order to increase synth. of DPPC



Sphingolipids


Diagnosis and treatment

• Diagnosis:

- Measure enzyme activity in cultured fibroblasts or peripheral leukocytes *v. easy to culture.* \Rightarrow biochemical test.
- Analyzing DNA (sequencing)

• Treatment:

- Recombinant human enzyme replacement therapy
 - Gaucher disease and Fabry disease (expensive)
- Bone marrow transplantation:
 - Gaucher disease
- Substrate reduction therapy
 - Gaucher disease: reducing the amount of glucocerebroside produced in the body pharmacologically



Ketogenesis

* ketogenesis is highly activated in diabetic patients causing diabetic ketoacidosis




Diabetic ketoacidosis

not diagnosed, incompitance to treatments


* DM patients, if uncontrolled → glc does NOT reach cells efficiently → stays in ↑ [] in the bloodstream → activation of fat degradation by ↑ glucagon & ↓ insulin → ↑ ketogenesis

- Normally,
 - Levels of ketone bodies: <3 mg/dl
 - 3HB:AcAc is ~1:1
3-hydroxybutyrate *acetoacetate*
- Under uncontrolled diabetes,
 - Levels of ketone bodies: 90 mg/dl and urinary excretion of ketone bodies may be 5,000 mg/24 hours. *→ acetone-like smell (bad) in urine.*
- The end-results:
 - Acidemia (ketoacidosis), dehydration and fruity odor of breath

↳ dragging ↑ H₂O mol due to ↑ [] of sugar in bld → kidneys unable to reabsorb → excreted in urine → drag ↑ H₂O dehydration ↑ frequent urination



Diabetic ketoacidosis



Increase Excretion in Urine as

Sodium Salt


↓
Loss of water

↓
Dehydration

Polyuria

Alcoholic ketoacidosis

- Alcohol also causes,
 - Acidemia (ketoacidosis)
- **But,**
 - **3HB:Ac is ~3:1**
 - *The ratio gets back to 1:1 after a few hours*
 - ***Gluconeogenesis is suppressed.***
 - ***Pyruvate is converted to lactate leading to hypovolemia, heart failure, and sepsis.***



Cholesterol Metabolism

Application: Cholelithiasis^{stone}

**stones formation is usually associated with over-saturation*

- \uparrow Cholesterol or \downarrow bile acids \rightarrow insolubility \rightarrow gallbladder stones (cholelithiasis)
- Treatment: cholecystectomy
 - Alternatively: oral administration of chenodeoxycholic acid results in a gradual (months to years) dissolution of the gallstones. \Rightarrow for less severe cases



Amino Acids

Clinical Hint: Abnormalities in protein digestion and Celiac disease

*problems with the pancreas.

*both result in deficiencies (i.e. vitamins)


Pancreatic secretion deficiency due to chronic pancreatitis, cystic fibrosis, or surgical removal of the pancreas, results in incomplete fat and protein digestion. \Rightarrow accumulate

Symptoms: abnormal appearance of lipids (steatorrhea), and undigested protein in the feces.

\hookrightarrow CANNOT be noted by patients themselves bcz H₂O-soluble.

Celiac disease (celiac sprue) is a disease of malabsorption resulting from immune-mediated damage to the small intestine in response to ingestion of gluten (or gliadin produced from gluten), a protein found in wheat, barley and rye.

\downarrow # of intestinal cells = \downarrow [intestinal enzymes] + \downarrow transporters for absorption



Clinical hint: Hyperammonemia

NH₃ has a neurotoxic effect on the CNS (tremors, slurring of speech, somnolence, vomiting, cerebral edema, and blurring of vision). At high concentrations, ammonia can cause coma and death.

Types:


Acquired hyperammonemia: Liver disease due to viral hepatitis, or to hepatotoxins such as alcohol.

Congenital hyperammonemia: Genetic deficiencies of any of the five enzymes of the urea cycle leads to failure to synthesize urea

The overall prevalence estimated to be 1:25,000 live births.

Ornithine transcarbamoylase deficiency is the most common

Treatment: restriction of dietary protein, administration of compounds that bind covalently to AAs, producing nitrogen-containing molecules that are excreted in the urine




Clinical hint: Homocysteine and vascular disease

↑ homocysteine = ↑ risk of CVD + other diseases.


High homocysteine promote oxidative damage, inflammation, and endothelial dysfunction, and increases risk for occlusive vascular disease

Homocysteine levels are inversely related to levels of folate, B12, and B6. → taken as supplements

Elevated homocysteine or decreased folic acid levels during pregnancy increases the incidence of neural tube defects (improper closure, as in spina bifida) in the fetus.



Metabolic disorders: Phenylketonuria (PKU)



↑ mutation of phenylalanine hydroxylase ⇒ accumulation of Phe → converted to other products including → phenylacetate, phenylpyruvate, phenyl lactate

The most common inborn error of amino acid metabolism (prevalence 1:15,000).

they can cross the BBB causing mental retardation & they have a musty odor

Due to phenylalanine hydroxylase deficiency

Biochemical changes: accumulation of phenylalanine (and a deficiency of tyrosine)

Tyr cannot be synthesized from Phe and becomes an essential amino acid.

Caused by any of 100 or more different mutations in the gene that codes for phenylalanine hydroxylase (PAH).

Characteristics of classic PKU:

*these problems don't appear at birth bcz the fetus uses the mother's enzymes to catalyze the rxn during pregnancy BUT if they consume Phe after birth → accumulation → disease

- Elevated phenylalanine in tissues, plasma, and urine.
- The characteristic musty “mousey” urine odor due to phenyllactate, phenylacetate, and phenylpyruvate


↳ can appear in patients if they don't stick to the dietary restrictions (their IQ ↓)

- **CNS symptoms:** Mental retardation (IQ < 50), failure to walk or talk, seizures, hyperactivity, tremor, microcephaly, and failure to grow

*since Tyr is used to make melanin pigment

- **Hypopigmentation:** fair hair, light skin color, and blue eyes because the hydroxylation of Tyr by tyrosinase (the first step in melanin formation) is competitively inhibited by the high levels of Phe.

Neonatal screening programs ⇒ biochemical test done early after birth (24-48 hrs)



Neonatal screening and diagnosis of PKU

PKU is treatable by dietary restriction.

Lack of neonatal symptoms

At birth, infants with PKU have normal blood levels of Phe because the mother clears the extra Phe through placenta

Exposure protein feeding for 24–48 hours elevates Phe, thus, screening should be done after this to avoid false negatives.

Treatment:

Dietary restriction: synthetic amino acid preparations low in Phe, supplemented with natural foods low in Phe content (fruits, vegetables, and certain cereals)

+ Tyr supplements bcz it is an essential aa

Earlier treatment (prevents neurologic damage days of life) prevents neurologic complications (mental retardation)

Aspartame should be avoided since it contains Phe.




Maternal PKU

- High blood Phe levels in the mother cause microcephaly, mental retardation, and congenital heart abnormalities in the fetus
- Phenylalanine is a teratogen (an agent or factor which causes malformation of an embryo). ⇒ cross the blood placental barrier.
- Dietary control of blood phenylalanine must begin prior to conception, and must be maintained throughout the pregnancy.



Metabolic disorders: Hyperphenylalaninemia



Dihydropteridine reductase deficiency: \Rightarrow accumulation of Phe \Rightarrow hyperphenylalaninemia

\hookrightarrow worse than PKU bcz enzyme is needed for multiple rxns

\hookrightarrow less conc. of catecholamines (NTs)

Restricting dietary Phe does not reverse the CNS effects due to deficiencies in neurotransmitters.

Replacement therapy with BH_4 or L-DOPA and 5-hydroxytryptophan (products of the affected tyrosine hydroxylase—and tryptophan hydroxylase—catalyzed reactions) improves the clinical outcome

Albinism

A group of conditions in which a defect in Tyr metabolism results in a deficiency in the production of melanin. (pigment)

Partial or full absence of pigment from the skin, hair, and eyes.

Inheritance modes: *⇒ diff. modes bcz there might be multiple genes affected in these patients*
AR (primary mode), AD, or X-linked.
autosomal recessive *autosomal dominant.* *↳ depending on the affected gene.*

Complete albinism (tyrosinase-negative oculocutaneous albinism) results from a deficiency of copper-requiring tyrosinase






Complete albinism:
The most severe form.
Total absence of pigment from the hair, eyes, and skin, vision defects and photophobia (sunlight hurts their eyes).
Higher risk for skin cancer.

Alkaptonuria (Alcaptonuria) ⇒ affected Tyr degradation.

A rare metabolic condition, however, cases were found in Jordan

A deficiency in homogentisic acid oxidase, resulting in the accumulation of homogentisic acid (a reaction that occurs in the degradative pathway of Tyr)

Characteristic symptoms: Not life threatening
Patients are usually asymptomatic until age 40.



-Homogentisic aciduria ⇒ if urine is static for 1 time it appears black.
→ destructs & damages the cartilage structure which explains signs & symptoms.

-Large joint arthritis → show symptoms like intervertebral disc dislocation.

-Black ochronotic pigmentation of cartilage and collagenous tissue

-Dark staining of the diapers can indicate the disease in infants

Treatment: diets low in protein—especially in Phe and Tyr reduce homogentisic acid levels, and the pigment deposited in body tissues.

Homocystinuria


Defects in the metabolism of homocysteine.

Mode of inheritance: AR

✗ relatively rare metabolic disease.

High plasma and urinary levels of homocysteine and Met and low levels of Cys.

The most common cause is a defect in cystathionine β -synthase that converts homocysteine to cystathionine



** affects metabolism of branched chain a.a.s. → they have their own pathway that starts with transamination, oxidative decarboxylation, oxidation (dehydrogenation)*

Maple syrup urine disease (MSUD)

Rare (1:185,000), autosomal recessive (AR) disorder, most cases are heterozygotes

Partial or complete deficiency in branched-chain α -keto acid dehydrogenase complex that decarboxylates Leu, Ile, and Val

Branched-chain amino acids are an important energy source in times of metabolic need

Accumulation in the blood causes a toxic effect that interferes with brain functions.

Signs and symptoms: feeding problems, vomiting, dehydration, severe metabolic acidosis, and a characteristic maple syrup odor to the urine.

If untreated, MSUD leads to mental retardation, physical disabilities, and even death.

Screening and diagnosis: prenatal diagnosis and neonatal screening are available.

Treatment: a synthetic formula that contains limited amounts of Leu, Ile, and Val to provide the branched-chain amino acids necessary for normal growth and development without producing toxic levels. *⇒ cannot be fully ditched.*

Early diagnosis and lifelong dietary treatment is essential for child normal development.

